Home Cart Sign in  
Chemical Structure| 128794-94-5 Chemical Structure| 128794-94-5

Structure of Mycophenolate Mofetil
CAS No.: 128794-94-5

Chemical Structure| 128794-94-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mycophenolate mofetil is a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase I/II with IC50 of 39 nM and 27 nM, respectively.

Synonyms: RS 61443; TM-MMF; MMF

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mycophenolate Mofetil

CAS No. :128794-94-5
Formula : C23H31NO7
M.W : 433.49
SMILES Code : O=C(OCCN1CCOCC1)CC/C(C)=C/CC2=C(O)C3=C(COC3=O)C(C)=C2OC
Synonyms :
RS 61443; TM-MMF; MMF
MDL No. :MFCD00867568
InChI Key :RTGDFNSFWBGLEC-SYZQJQIISA-N
Pubchem ID :5281078

Safety of Mycophenolate Mofetil

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Dehydrogenase

    Inosine monophosphate dehydrogenase II, IC50:27 nM

    Inosine monophosphate dehydrogenase I, IC50:39 nM

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
MRL-(Fas)lpr mice Spontaneous autoimmune tissue injury model Oral 100 mg/kg Daily administration for 8 weeks To compare the therapeutic effects of Cat-S inhibitor RO5459072 and MMF on systemic autoimmunity and lupus nephritis. RO5459072 dose-dependently reversed aberrant systemic autoimmunity (e.g., plasma cytokines, activation of myeloid cells, and hypergammaglobulinemia) and significantly suppressed IgG autoantibody production. RO5459072 also dose-dependently improved the pathological scores and proteinuria in lupus nephritis, with effects superior to MMF. PMC5459853
C3H/HeNHsd mice CBV3-induced myocarditis model Oral gavage 100, 200 or 300 mg/kg/day Twice daily for 7 consecutive days Evaluate the protective effect of MMF on CBV3-induced myocarditis, results showed MMF significantly reduced the number of myocarditis foci PMC317291
NZB/W F1 mice Lupus nephritis model Oral gavage 100 mg/kg Once daily for 4 weeks MMF significantly reduced serum CD44 and VCAM-1 levels to pre-nephritic levels, improving kidney inflammation and fibrosis PMC11473352
MRL/lpr mice Lupus nephritis model Oral 50 mg/kg Once daily for 8 weeks To evaluate the efficacy of multitarget therapy (MT) in the treatment of lupus nephritis, results showed that MT therapy significantly improved systemic immune activation and renal injury. PMC11773216
NZB/W F1 mice Lupus nephritis model Oral gavage 100 mg/kg Daily administration for 24 weeks To evaluate the therapeutic effect of mycophenolate mofetil on lupus nephritis. Results showed that mycophenolate mofetil significantly reduced proteinuria, improved survival, and attenuated tubulointerstitial inflammation and glomerular damage. PMC5083145
C3H mice Immunosuppressed mouse model Oral gavage 40 mg/kg Daily for 13 days To study the role of mycophenolate mofetil in an immunosuppressive regimen mimicking the state of lung transplant recipients. PMC11705917
Mice Myocardial infarction model Intraperitoneal injection 20 mg/kg/day Daily until analysis Attenuate immune response and promote cardiac reprogramming PMC11637486

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05627739 Vogt-Koyanagi-Harada Disease|M... More >>ycophenolate Mofetil Less << RECRUITING 2025-12-01 xiaomin Zhang, Tianjin, Tianji... More >>n, 300000, China Less <<
NCT00893958 Prophylaxis of Organ Rejection COMPLETED 2025-01-06 CEDRA Clinical Research, Austi... More >>n, Texas, 78759, United States Less <<
NCT00893542 Prophylaxis of Organ Rejection COMPLETED 2025-11-05 CEDRA Clinical Research, LLC, ... More >>Austin, Texas, 78759, United States Less <<
NCT05951517 Henoch-Sch?nlein Purpura|Gastr... More >>ointestinal Injury|Mycophenolate Mofetil Less << RECRUITING 2026-12-31 Sun Yat-sen Memorial Hospital,... More >> Sun Yat-sen University, Guangzhou, Guangdong, 510120, China Less <<
NCT00367146 Liver Transplantation|Chronic ... More >>Kidney Disease Less << COMPLETED 2025-08-08 Hannover medical School, Hanno... More >>ver, 30625, Germany Less <<
NCT05129410 Idiopathic Inflammatory Myopat... More >>hy|Interstitial Lung Disease Less << PHASE4 UNKNOWN 2023-11-30 Department of Rheumatology,the... More >> First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China Less <<
NCT00894088 Prophylaxis of Organ Rejection COMPLETED 2025-01-06 CEDRA Clinical Research, Austi... More >>n, Texas, 78759, United States Less <<
NCT04868786 Hematopoietic Stem Cell Transp... More >>lantation Less << PHASE1 RECRUITING 2025-10-25 Seoul National University Hosp... More >>ital, Seoul, 03080, Korea, Republic of Less <<
NCT00001764 Vasculitis|Wegener's Granuloma... More >>tosis Less << PHASE1 COMPLETED 2025-06-04 National Institute of Allergy ... More >>and Infectious Diseases (NIAID), Bethesda, Maryland, 20892, United States Less <<
NCT05101447 Lupus Nephritis PHASE2 WITHDRAWN 2025-07-24 -
NCT01283867 FED PHASE1 COMPLETED 2025-12-07 Lambda Therapeutic Research Lt... More >>d, Bodakdev, Ahmedabad, 3 80 054, India Less <<
NCT00166153 Cardiac Transplantation TERMINATED 2025-05-05 Children's Healthcare of Atlan... More >>ta, Atlanta, Georgia, 30322, United States Less <<
NCT00531635 Post Transplant in Immunosuppr... More >>ession w/CSA & Mycophenolate Mofetil Less << PHASE1 UNKNOWN 2025-06-12 KFSH&RC, Riyadh, 11211, Saudi ... More >>Arabia Less <<
NCT03920059 Lupus Nephritis PHASE4 TERMINATED 2020-01-30 King Chulalongkorn Memorial Ho... More >>spital, Bangkok, Please Select, 10330, Thailand Less <<
NCT00166244 De Novo Renal Transplant Recip... More >>ient. Less << PHASE4 COMPLETED 2025-04-06 John Hunter Hospital, New Lamb... More >>ton, New South Wales, 2305, Australia|Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|St Vincent's Hospital, Melbourne, Victoria, 3065, Australia|Royal Melbourne Hospital, Parkville, Victoria, 3052, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Royal Perth Hospital, Perth, Western Australia, 6847, Australia|Med. Univ. Klinik, Graz, 8036, Austria|AKH Wien, Vienna, Vienna, Austria|University Hospitals Leuven, Leuven, 3000, Belgium|Hospital do Rim e Hipertensao, Sao Paulo, CEP 0438-002, Brazil|Vancouver General Hospital, Vancouver, British Columbia, V5Z 1M9, Canada|Ruijin Hospital, Shanghai, Shanghai, 200001, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Odense University Hospital, Odense, 5000, Denmark|Surgical Clinic Of Tartu University Clinics, Tartu, 51014, Estonia|Hopital Pellegrin, C.H.R.de Bordeaux, Bordeaux, 33076, France|Hospital du Bocage, Dijon, 21000, France|CHU de Grenoble, Grenoble, 38043, France|CHU Kremlin Bicêtre, Kremlin Bicêtre, 94275, France|Hopital Calmette, Lille, 59037, France|Hopital Jeanne de Flandres, Lille, 59037, France|Centre Hospitalier Regional Universitaire, Limoges, 87042, France|CHU Hotel Dieu, Nantes, 44093, France|Hopital Necker, Paris, 75015, France|Hopital Tenon, Paris, 75020, France|Centre Hospitalier Lyon Sud, Pierre Benite, 69495, France|Hopital Foch, Suresnes, 92151, France|CHU Purpan, Toulouse, 31059, France|CHU Rangueil, Toulouse, 31059, France|CHU de Nancy-Brabois, Vandoeuvre-les-Nancy, 54511, France|Universitatsklinikum Charite, Berlin, 10098, Germany|Chirurgische Universit?tsklinik, Freiburg, 79106, Germany|Universitatsklinikum Heidelberg, Heidelberg, 69120, Germany|University of Heidelberg, Heidelberg, 69120, Germany|Stadt Kliniken Koln, Koln, 51009, Germany|University Hospital Wurzburg, Wurzburg, 97080, Germany|Vilnius University Hospital, Vilnius, 2021, Lithuania|Leids Universitair Medisch Centrum, Leiden, 2333, Netherlands|Erasmus Medical Center Rotterdam, Rotterdam, 3000, Netherlands|Rikshopitalet, Oslo, 0027, Norway|Institute of Transplantology, Medical University of Warsaw, Warsaw, 02-006, Poland|Children's Memorial Health Institute, Warsaw, 04-736, Poland|Hospital Son Dureta, Palma De Mallorca, 07014, Spain|Hospital Infanta Christa, Badajoz, 06080, Spain|Hospital Del Mar, Barcelona, 08003, Spain|Valle de Hebron, Barcelona, 08035, Spain|Hospital Sant Joan de Deu, Barcelona, 8950, Spain|Hospital Reina Sofia, Cordoba, 14004, Spain|Hospital de las Nieves, Granada, 18014, Spain|Hospital Ramon Y Cajal, Madrid, 28034, Spain|Fundacion Jimenez Diaz, Madrid, 28040, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|La Paz, Madrid, 28046, Spain|Complejo Hospitalario Univeritario de Santiago, Santiago De Compostela, 15706, Spain|Hospital Virgen del Rocio, Sevilla, 41013, Spain|Hospital Dr. Peset, Valencia, Spain|University Hospital, Malmo, Malmo, 205 02, Sweden|Karolinska University Hospital, Huddinge, Stockholm, 141 86, Sweden|University Hospital A, Uppsala, 751 85, Sweden|National Taiwan University Hospital, Taipei, Taiwan|Royal Free Hospital, London, NW3 2QG, United Kingdom|Guys and St Thomas's Hospital, London, SE1 9RT, United Kingdom|St George's Hospital, London, SW17 ORE, United Kingdom|Hospital "Miguel Perez Carreno", Caracas, Venezuela|Hospital Universitario de Caracas, Caracas, Venezuela|Hospital Universitario de Maracaibo, Maracaibo, Venezuela Less <<
NCT00187941 Transplantation, Renal|Immunos... More >>uppression Less << EARLY_PHASE1 COMPLETED 2025-11-06 University of Florida, Gainesv... More >>ille, Florida, 32610, United States Less <<
NCT00217152 Kidney Transplantation|Delayed... More >> Graft Function Less << PHASE4 TERMINATED 2025-08-07 Mayo Clinic, Rochester, Minnes... More >>ota, 55905, United States Less <<
NCT03517982 Acute Transplant Rejection in ... More >>Patients Receiving Allogeneic Renal Transplant Less << COMPLETED 2025-09-16 Prince Hamza Hospital, Amman, ... More >>Jordan Less <<
NCT00199667 Kidney Transplant Recipients PHASE4 UNKNOWN - Néphrologie, Amiens, 80000, Fr... More >>ance|Néphrologie, Angers, 49000, France|Néphrologie, Caen, 14000, France|Néphrologie, Limoges, 87042, France|Néphrologie, Paris, 75000, France|Néphrologie, Poitiers, 86000, France|Néphrologie, Reims, 51000, France|Néphrologie, Rouen, 76000, France|Néphrologie, Strasbourg, 67000, France|Néphrologie, Toulouse, 31059, France|Néphrologie, Tours, 37000, France Less <<
NCT01283841 Fasting PHASE1 COMPLETED 2025-12-07 Lambda Therapeutic Research Lt... More >>d, Bodakdev, Ahmedabad, 3 80 054, India Less <<
NCT00433186 Diffuse Cutaneous Systemic Scl... More >>erosis Less << PHASE1 COMPLETED 2025-03-11 Boston University School of Me... More >>dicine, Boston, Massachusetts, 02118, United States Less <<
NCT00004567 Vasculitis|Wegener's Granuloma... More >>tosis Less << PHASE2 COMPLETED 2025-06-04 National Institute of Allergy ... More >>and Infectious Diseases (NIAID), Bethesda, Maryland, 20892, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.53mL

2.31mL

1.15mL

23.07mL

4.61mL

2.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories